New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
05:55 EDTAGN, AGN, SE, SE, NYX, NYX, K, K, EL, EL, EMR, EMR, ETN, ETN, DO, DO, DLPH, DLPH, CSC, CSC, CAH, CAH, BDX, BDX, ADP, ADP, ADM, ADM, TE, TECompanies reporting Before the Market Open on Tuesday, February 5
Notable companies reporting before the opening bell include Allergan (AGN), Archer Daniels Midland (ADM), Automatic Data Processing (ADP), Becton Dickinson and Co (BDX), Cardinal Health (CAH), Computer Sciences (CSC), Delphi Automotive (DLPH), Diamond Offshore Drilling (DO), Eaton (ETN), Emerson Electric (EMR), Estee Lauder Companies (EL), Kellogg (K), NYSE Euronext (NYX), Spectra Energy (SE) and TECO Energy (TE).
News For AGN;ADM;ADP;BDX;CAH;CSC;DLPH;DO;ETN;EMR;EL;K;NYX;SE;TE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
August 26, 2015
09:28 EDTEMREmerson upgraded to Buy from Hold at Vertical Research
Subscribe for More Information
09:20 EDTBDXFluidigm has negative read through from Becton Dickinson deal, says Leerink
Subscribe for More Information
09:03 EDTETNEaton upgraded to Buy from Hold at Vertical Research
08:15 EDTEMREmerson reports supports estimate for muted Fastenal growth, says William Blair
Subscribe for More Information
06:01 EDTSESpectra Energy upgraded to Buy from Neutral at UBS
UBS upgraded Spectra Energy to Buy citing favorable risk/reward. The firm said the commodity market overhang is overstated given Spectra's infrastructure being predominantly FERC regulated and long dated contracts, and its growth rate is unchanged while peers have been forced to lower growth forecasts.
August 25, 2015
18:11 EDTDOTranocean tanks after proposing dividend cancellations, peers follow
Subscribe for More Information
16:09 EDTBDXBecton Dickinson unit acquires Cellular Research to develop genomics platform
Subscribe for More Information
10:21 EDTCAHCardinal Health to acquire majority stake in naviHealth
Cardinal Health announced that it is acquiring a majority stake in naviHealth and expects the transaction to close later this week. Privately-held naviHealth partners with health plans, health systems and providers to manage the post-acute segment of the care continuum. naviHealth's principal investor, Welsh, Carson, Anderson & Stowe, along with management, will continue to have an ownership interest in the business. Cardinal Health said it is acquiring 71% of naviHealth for approximately $290M, with a goal of acquiring the entire business within four years, in accordance with a series of call/put rights during that period of time. Cardinal expects this acquisition to be neutral to its FY16 non-GAAP diluted earnings per share from continuing operations as it is a partial period, and slightly accretive to non-GAAP diluted earnings per share from continuing operations beginning in FY17, the first full year post close. "From a GAAP perspective, it is too early in the process to provide any specific guidance on the amortization of intangible assets. Once the fair value estimates are complete, we will provide additional details. Recall that our FY16 assumptions provided on our earnings call on July 30, 2015 only included those acquisitions that had been completed through June 30," the company stated in an FAQ document related to the deal.
09:44 EDTEMREmerson says 3-month July orders growth down 15%-20%
Subscribe for More Information
09:26 EDTCAHRBC Capital to hold a bus tour
Healthcare Bus Tour travels throughout Nashville, TN to visit with various healthcare companies on August 25-26.
08:47 EDTKKellogg names Carolyn Tastad to board of directors
Subscribe for More Information
08:46 EDTKKellogg elects Noel Wallace to board
Kellogg (K) announced the election of Noel R. Wallace, president of Colgate-Palmolive (CL) Latin America, to its board of directors effective October 1, 2015.
08:14 EDTAGNAllergan multiple is low, says Leerink
Leerink predicts that Allergan's 2016 EPS will come in at $17-$18. The firm thinks the company has "durable revenue streams," and a "deep pipeline with several potential blockbuster candidates." Leerink adds that the company "has significant capacity for M&A." It keeps a $388 price target and Outperform rating on the shares.
07:29 EDTBDXBecton Dickinson acquisition positive, says Stifel
Subscribe for More Information
06:32 EDTDLPHDelphi receives LOI regarding 6.4% of HellermannTyton shares, Reuters says
Subscribe for More Information
August 24, 2015
08:37 EDTAGNAllergan recalls certain lots of REFRESH, FML, Blephamide treatments
Allergan announced that it is conducting a voluntary recall down to consumer level of specific lots of its REFRESH Lacri-Lube 3.5g and 7g for dry eye, REFRESH P.M. 3.5g for dry eye, FML 0.1%, and Blephamide 10%/0.2% sterile topical ophthalmic ointment combining an antibacterial and a corticosteroid, 3.5g. Allergan chose to initiate this recall based on a small number of customer complaints which reported a small black particle at the time of use. Allergan has informed the U.S. Food and Drug Administration of this voluntary recall. Allergan is contacting retailers and wholesalers who have been shipped affected product lots to initiate the recall and is informing them of the steps needed to return affected product.
August 21, 2015
09:26 EDTELEstee Lauder should be bought on weakness, says RBC Capital
RBC Capital believes that Estee Lauder's multi-year growth story is intact. The firm says that in the last five times that the stock has fallen 5%, it has subsequently rebounded strongly. RBC cut tis price target on the name to $105 from $110 but keeps an Outperform rating.
August 20, 2015
08:16 EDTAGNAllergan's Botox resubmission for lower limb spasticiy accepted by FDA
Allergan 's resubmission of its Supplemental Biologics License Application for Botox for the treatment of adults with lower limb spasticity in adults has been accepted by the FDA. A six-month review period has been assigned for the sBLA. The Prescription Drug User Fee Act date is expected to be in 1Q16. The resubmission provides additional data from a double-blind, placebo controlled study involving 468 patients with lower limb spasticity. The FDA also approved an increase to the maximum Botox cumulative dose within three months from 360 to 400 units in adults treated for one or more indications.
August 19, 2015
08:53 EDTEMREmerson management to meet with Oppenheimer
Subscribe for More Information
06:08 EDTBDXFDA warns 'do not use' compounded drugs stored in BD 3ml, 5ml syringes
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use